OOIR: Observatory of International Research

Papers

(The H4-Index of Lancet HIV is 40. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Tackling cancer risk in adolescents and young adults with HIV	197
Invest in HIV now to reap future rewards	174
Inherited fear: 40 years of HIV/AIDS in the UK	154
The time to end the war on drugs is long overdue	131
A new initiative to track HIV resource allocation	125
Rapid access to antiretroviral therapy, receipt of naltrexone, and strengths-based case management versus standard of care for HIV viral load suppression in people with HIV who inject drugs in Russia	125
Highlights of HIV Drug Therapy 2022	123
Costs and outcomes of routine HIV oral pre-exposure prophylaxis implementation across different service delivery models and key populations in South Africa: a retrospective cohort study	119
Treating HIV-associated tuberculosis in children without compromise	118
Optimising HIV spending in eastern Europe and central Asia	114
Trauma-informed HIV prevention for forcibly displaced adolescents and young adults	106
Reflections on a decade of The Lancet HIV	106
A career dedicated to public service	91
Safety and drug quantification of the dapivirine vaginal ring and oral pre-exposure prophylaxis in breastfeeding mother–infant pairs (MTN-043): a phase 3B, open-label, randomised trial	87
Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-labe	86
PEPFAR reauthorisation hangs in the balance	84
Planning for PrEP: are national surveillance data sufficient?	80
UNAIDS strategy aligns HIV priorities with development goals	78
Empowering women: addressing HIV vertical transmission in the Philippines	76
Dolutegravir for children with HIV-associated tuberculosis	75
Gone but not forgotten	75
Zvandiri—when medicines alone are not enough	63
How much could long-acting PrEP cost in South Africa?	61
AIDS activism from the beginning	59
Combination HIV prevention reduces orphanhood in Uganda	57

Transitioning youth living with HIV to adult HIV care	55
HIV and mental health services for female sex workers	55
The Australian AIDS crisis through the eyes of volunteers	54
HIV-related CNS infections: translating DREAMM into reality	53
Risk estimation in HIV reveals our usual blind spots	51
Steps toward quick and equitable roll-out of lenacapavir	48
Interpreting unit costs of PrEP services by effective use	47
Controversial chronicler of LGBTQ rights	47
The Háttér Society: supporting LGBTQ people in Hungary	44
UK HIV transmission drops in the wake of COVID-19	42
Rates of viral suppression in a cohort of people with stable HIV from two community models of ART delivery versus facility-based HIV care in Lusaka, Zambia: a cluster-randomised, non-inferiority trial	41
Improvements in transition times through the HIV cascade of care among gay and bisexual men with a new HIV diagnosis in New South Wales and Victoria, Australia (2012–19): a longitudinal cohort study	41
All the viral loads we cannot see	41
Subnational mapping of HIV incidence and mortality among individuals aged 15–49 years in sub-Saharan Africa, 2000–18: a modelling study	40
Ageing with HIV: is the virus or the treatment guilty?	40
Safety and immunogenicity of a polyvalent DNA–protein HIV vaccine with matched Env immunogens delivered as a prime–boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a pha	40
Evidence supports use of on-demand PrEP for HIV prevention	40
Community mobilisation to achieve HIV testing and care goals	40